NFE2L2 and cancer: Aberrant activation of NRF2 in cancer is attributed to either gain-of-function mutations in the NRF2 encoding gene NFE2L2 or loss of function of its suppressor, Kelch-like ECH-associated protein 1 (KEAP1).